The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome

(2016) L. Trementino et al.   HORMONE AND METABOLIC RESEARCH

Complications of Cushing's syndrome: state of the art

(2016) Rosario Pivonello et al.   Lancet Diabetes & Endocrinology

The Treatment of Cushing's Disease

(2015) Rosario Pivonello et al.   ENDOCRINE REVIEWS

The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease

(2015) K. Hayashi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

(2015) Lynnette K. Nieman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Genetics of Cushing’s disease: an update

(2015) L. G. Perez-Rivas et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

(2014) Rosario Pivonello et al.   CLINICAL ENDOCRINOLOGY

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

(2014) Jochen Schopohl et al.   Pituitary

Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations

(2014) Laura Trementino et al.   Pituitary

Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study

(2013) Astrid Breitschaft et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effective Long-Term Treatment of Cushing's Disease with Pasireotide: A Case Report

(2013) Lin Lu et al.   Endocrine Practice

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Practice Guidelines for the Management of Hypertension in the Community

(2013) Michael A. Weber et al.   Journal of Clinical Hypertension

Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial

(2013) Jessica MacKenzie Feder et al.   Pituitary

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

(2013) M. Boscaro et al.   Pituitary

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

(2013) Annamaria Colao et al.   Pituitary

Pasireotide for the treatment of Cushing's disease

(2013) Annamaria Colao et al.   Expert Opinion on Orphan Drugs

Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide

(2012) Y. Reznik et al.   DIABETES & METABOLISM

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease

(2008) Kimberly Cukier et al.   CLINICAL ENDOCRINOLOGY

Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement

(2008) B. M. K. Biller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial

(2008) M. Boscaro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM